Ixekizumab
Indication
Treatment of active psoriatic arthritis in adults after inadequate response to DMARDs
NICE TA537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Red
Brand:
Taltz®
Nice TA:
537
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if:
- it is used as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
- the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after the first 12 weeks or
- TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).